Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease

Amber Tong

When AB Science claimed a breakout win in Alzheimer’s disease for masitinib, its all-purpose tyrosine kinase inhibitor, in late December, CEO Alain Moussy pointed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

Clin­i­cal stud­ies for AB Sci­ence's all-pur­pose an­ti-in­flam­ma­to­ry drug grind to a halt as com­pa­ny flags po­ten­tial risk of heart dis­ease

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Clinical studies for AB Science's all-purpose anti-inflammatory drug grind to a halt as company flags potential risk of heart disease